Risk factors and prevention of proliferative vitreoretinopathy

Denis Jusufbegovic, Shigeo Tamiya, Henry J. Kaplan

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Proliferative vitreoretinopathy (PVR) is the most common complication after repair of a retinal detachment. It is a clinical syndrome characterized by fibrocellular proliferation resulting in the formation of fibrotic epiretinal (i.e., preretinal and subretinal) membranes. Despite improvements in surgical techniques and anatomical outcomes, the treatment of PVR remains a challenge to preserve functional vision. PVR represents a wound healing response and multiple cytokines and growth factors may play a key role in its development. One of the most critical steps in the development of PVR is transformation of retinal pigment epithelium cells into fibroblastic and myofibroblastic phenotypes, which results in proliferation of fibrocellular membranes. Contraction of the membranes causes tractional retinal detachment. Treatment of PVR includes meticulous removal of fibrocellular membranes, relieving traction on all retinal breaks and intraocular tamponade. Several pharmacologic agents have demonstrated effectiveness in preventing the contraction of fibrocellular membranes in experimental models of PVR.

Original languageEnglish (US)
Pages (from-to)431-440
Number of pages10
JournalExpert Review of Ophthalmology
Volume10
Issue number5
DOIs
StatePublished - Sep 3 2015
Externally publishedYes

Fingerprint

Proliferative Vitreoretinopathy
Membranes
Retinal Detachment
Retinal Perforations
Pigments
Retinal Pigment Epithelium
Traction
Repair
Wound Healing
Intercellular Signaling Peptides and Proteins
Theoretical Models
Cytokines
Phenotype

Keywords

  • animal model of proliferative vitreoretinopathy treatment
  • pathogenesis
  • proliferative vitreoretinopathy
  • scleral buckle
  • silicone oil
  • tamponade
  • vitrectomy

ASJC Scopus subject areas

  • Biomedical Engineering
  • Ophthalmology
  • Optometry

Cite this

Risk factors and prevention of proliferative vitreoretinopathy. / Jusufbegovic, Denis; Tamiya, Shigeo; Kaplan, Henry J.

In: Expert Review of Ophthalmology, Vol. 10, No. 5, 03.09.2015, p. 431-440.

Research output: Contribution to journalReview article

Jusufbegovic, Denis ; Tamiya, Shigeo ; Kaplan, Henry J. / Risk factors and prevention of proliferative vitreoretinopathy. In: Expert Review of Ophthalmology. 2015 ; Vol. 10, No. 5. pp. 431-440.
@article{1f360dd5c56a43369cb13b55d4d2fc36,
title = "Risk factors and prevention of proliferative vitreoretinopathy",
abstract = "Proliferative vitreoretinopathy (PVR) is the most common complication after repair of a retinal detachment. It is a clinical syndrome characterized by fibrocellular proliferation resulting in the formation of fibrotic epiretinal (i.e., preretinal and subretinal) membranes. Despite improvements in surgical techniques and anatomical outcomes, the treatment of PVR remains a challenge to preserve functional vision. PVR represents a wound healing response and multiple cytokines and growth factors may play a key role in its development. One of the most critical steps in the development of PVR is transformation of retinal pigment epithelium cells into fibroblastic and myofibroblastic phenotypes, which results in proliferation of fibrocellular membranes. Contraction of the membranes causes tractional retinal detachment. Treatment of PVR includes meticulous removal of fibrocellular membranes, relieving traction on all retinal breaks and intraocular tamponade. Several pharmacologic agents have demonstrated effectiveness in preventing the contraction of fibrocellular membranes in experimental models of PVR.",
keywords = "animal model of proliferative vitreoretinopathy treatment, pathogenesis, proliferative vitreoretinopathy, scleral buckle, silicone oil, tamponade, vitrectomy",
author = "Denis Jusufbegovic and Shigeo Tamiya and Kaplan, {Henry J.}",
year = "2015",
month = "9",
day = "3",
doi = "10.1586/17469899.2015.1090875",
language = "English (US)",
volume = "10",
pages = "431--440",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Risk factors and prevention of proliferative vitreoretinopathy

AU - Jusufbegovic, Denis

AU - Tamiya, Shigeo

AU - Kaplan, Henry J.

PY - 2015/9/3

Y1 - 2015/9/3

N2 - Proliferative vitreoretinopathy (PVR) is the most common complication after repair of a retinal detachment. It is a clinical syndrome characterized by fibrocellular proliferation resulting in the formation of fibrotic epiretinal (i.e., preretinal and subretinal) membranes. Despite improvements in surgical techniques and anatomical outcomes, the treatment of PVR remains a challenge to preserve functional vision. PVR represents a wound healing response and multiple cytokines and growth factors may play a key role in its development. One of the most critical steps in the development of PVR is transformation of retinal pigment epithelium cells into fibroblastic and myofibroblastic phenotypes, which results in proliferation of fibrocellular membranes. Contraction of the membranes causes tractional retinal detachment. Treatment of PVR includes meticulous removal of fibrocellular membranes, relieving traction on all retinal breaks and intraocular tamponade. Several pharmacologic agents have demonstrated effectiveness in preventing the contraction of fibrocellular membranes in experimental models of PVR.

AB - Proliferative vitreoretinopathy (PVR) is the most common complication after repair of a retinal detachment. It is a clinical syndrome characterized by fibrocellular proliferation resulting in the formation of fibrotic epiretinal (i.e., preretinal and subretinal) membranes. Despite improvements in surgical techniques and anatomical outcomes, the treatment of PVR remains a challenge to preserve functional vision. PVR represents a wound healing response and multiple cytokines and growth factors may play a key role in its development. One of the most critical steps in the development of PVR is transformation of retinal pigment epithelium cells into fibroblastic and myofibroblastic phenotypes, which results in proliferation of fibrocellular membranes. Contraction of the membranes causes tractional retinal detachment. Treatment of PVR includes meticulous removal of fibrocellular membranes, relieving traction on all retinal breaks and intraocular tamponade. Several pharmacologic agents have demonstrated effectiveness in preventing the contraction of fibrocellular membranes in experimental models of PVR.

KW - animal model of proliferative vitreoretinopathy treatment

KW - pathogenesis

KW - proliferative vitreoretinopathy

KW - scleral buckle

KW - silicone oil

KW - tamponade

KW - vitrectomy

UR - http://www.scopus.com/inward/record.url?scp=84942371631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942371631&partnerID=8YFLogxK

U2 - 10.1586/17469899.2015.1090875

DO - 10.1586/17469899.2015.1090875

M3 - Review article

VL - 10

SP - 431

EP - 440

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 5

ER -